Market research
BLRX BioLineRx Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12M
- P/E ratio
- 0.0
- Analyst target
- 23
- Dividend yield
- Not available
- Beta
- 0.71
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US09071M3043
- Market cap
- 12M
- P/E ratio
- 0.0
- Analyst target
- 23
- Dividend yield
- Not available
- Beta
- 0.71
About
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BLRX discussion.
5 years, 4 months ago
BioLineRx Ltd is currently in a long term uptrend where the price is trading 20.7% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
BioLineRx Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 21.5% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.3% to $-5M since the same quarter in the previous year.
Based on the above factors, BioLineRx Ltd gets an overall score of 3/5.